News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Infinity Pharmaceuticals Inc. (INFI) Reports Phase 1 Data for IPI-145 at American College of Rheumatology/ARHP Supporting Development in Inflammatory Conditions



11/12/2012 10:18:44 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced new data from its completed Phase 1 study of IPI-145, the company’s potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The data showed that IPI-145 was well tolerated and demonstrated favorable pharmacokinetics following administration of single and multiple doses in healthy adult subjects. Infinity also presented data demonstrating the activity of IPI-145 in preclinical models of rheumatoid arthritis (RA). These findings were presented at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) 2012 Annual Meeting held in Washington, DC.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES